CVRx, Inc. (NASDAQ:CVRX) Given Consensus Rating of “Moderate Buy” by Brokerages

CVRx, Inc. (NASDAQ:CVRX) has earned a consensus rating of “Moderate Buy” from the seven brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $14.00.

A number of research firms recently issued reports on CVRX. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $11.00 price target on shares of CVRx in a research note on Tuesday, August 5th. William Blair raised shares of CVRx to a “strong-buy” rating in a research note on Monday, July 7th.

CVRx Price Performance

Shares of NASDAQ:CVRX opened at $7.87 on Friday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 10.78 and a current ratio of 11.99. The firm has a fifty day moving average price of $7.64 and a 200 day moving average price of $8.00. CVRx has a fifty-two week low of $4.30 and a fifty-two week high of $18.55. The firm has a market cap of $205.80 million, a price-to-earnings ratio of -3.75 and a beta of 1.26.

CVRx (NASDAQ:CVRX) last released its quarterly earnings results on Monday, August 4th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.05). The business had revenue of $13.59 million for the quarter, compared to analysts’ expectations of $13.22 million. CVRx had a negative net margin of 95.61% and a negative return on equity of 79.31%. CVRx has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, sell-side analysts expect that CVRx will post -1.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CVRx

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Cresset Asset Management LLC increased its stake in CVRx by 3.5% in the 2nd quarter. Cresset Asset Management LLC now owns 53,542 shares of the company’s stock worth $315,000 after buying an additional 1,823 shares during the period. Rhumbline Advisers increased its stake in CVRx by 13.0% in the 1st quarter. Rhumbline Advisers now owns 19,018 shares of the company’s stock worth $233,000 after buying an additional 2,192 shares during the period. Larson Financial Group LLC purchased a new position in CVRx in the 1st quarter worth about $28,000. Deutsche Bank AG increased its stake in CVRx by 41.5% in the 1st quarter. Deutsche Bank AG now owns 10,390 shares of the company’s stock worth $127,000 after buying an additional 3,048 shares during the period. Finally, Tradewinds LLC. increased its stake in CVRx by 5.8% in the 1st quarter. Tradewinds LLC. now owns 58,011 shares of the company’s stock worth $709,000 after buying an additional 3,175 shares during the period. Hedge funds and other institutional investors own 75.27% of the company’s stock.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.